T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your breast cancer is HER2-positive (a type that grows due to a protein called HER2).
- Your cancer has spread or come back and cannot be removed with surgery.
- You have already been treated with trastuzumab and taxane chemotherapy.
- You have not had treatment with an ADC drug (like T-DM1) or a CDK4/6 inhibitor before.
- You have not had any other cancer in the past 5 years, except for certain early-stage or non-invasive cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests a targeted drug combination for HER2-positive, hormone-receptor-positive breast cancer that has spread. It aims to shrink tumors and control the disease for as long as possible, with a planned switch to maintenance therapy after initial response.
Hear when a new HER2-positive Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.